BioXcel Therapeutics Inc (BTAI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioXcel Therapeutics Inc (BTAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11131
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioXcel Therapeutics Inc (BioXcel Therapeutics) a subsidiary of BioXcel Corp is a clinical stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. Its pipeline product portfolio includes BXCL501, an adrenergic agent with a sublingual route of administration is used for treating neuropsychiatric and neurodegenerative diseases; BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers; BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology intravenous compound for hematological malignancies. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates with big data and proprietary machine learning algorithms to develop new therapeutic candidates. BioXcel Therapeutics is headquartered in New Haven, Connecticut, the US.

BioXcel Therapeutics Inc (BTAI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 10
Equity Offering 11
BioXcel Therapeutics Raises USD60 Million in IPO of Shares 11
BioXcel Therapeutics Raises USD0.2 Million in Private Placement 13
BioXcel Therapeutics Raises USD0.5 Million in Private Placement of Shares 14
BioXcel Therapeutics Raises Funds through Private Placement of Shares 15
BioXcel Therapeutics Raises USD0.2 Million in Private Placement of Shares 16
BioXcel Therapeutics Raises USD1.8 Million in Private Placement of Shares 17
BioXcel Therapeutics Inc – Key Competitors 18
BioXcel Therapeutics Inc – Key Employees 19
BioXcel Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
May 14, 2018: BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioXcel Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 10
BioXcel Therapeutics Raises USD60 Million in IPO of Shares 11
BioXcel Therapeutics Raises USD0.2 Million in Private Placement 13
BioXcel Therapeutics Raises USD0.5 Million in Private Placement of Shares 14
BioXcel Therapeutics Raises Funds through Private Placement of Shares 15
BioXcel Therapeutics Raises USD0.2 Million in Private Placement of Shares 16
BioXcel Therapeutics Raises USD1.8 Million in Private Placement of Shares 17
BioXcel Therapeutics Inc, Key Competitors 18
BioXcel Therapeutics Inc, Key Employees 19

List of Figures
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioXcel Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[BioXcel Therapeutics Inc (BTAI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NeuroSearch AS (NEUR):企業の財務・戦略的SWOT分析
    NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • J.K. Cement Ltd (JKCEMENT):企業の財務・戦略的SWOT分析
    J.K. Cement Ltd (JKCEMENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Provectus Biopharmaceuticals Inc (PVCT)-製薬・医療分野:企業M&A・提携分析
    Summary Provectus Biopharmaceuticals Inc (Provectus), formerly Provectus pharmaceuticals Inc is a biotechnology company that develops pharmaceuticals for oncology and dermatology indications. The company provides pipeline products such as PV-10 for recurrent melanoma, PV-10 for metastatic liver canc …
  • Wintershall Holding GmbH:石油・ガス:M&Aディール及び事業提携情報
    Summary Wintershall Holding GmbH (Wintershall) explores for production of oil and natural gas. It operates as a subsidiary of BASF Group. The company holds expertise in conducting geological studies, geophysical measurements, seismic surveys, reservoir modeling, field development, onshore and offsho …
  • MEI Pharma Inc (MEIP):企業の財務・戦略的SWOT分析
    MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Taghleef Industries L.L.C.
    Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • NeoDynamics AB:企業の製品パイプライン分析
    Summary NeoDynamics AB (NeoDynamics) is a medical technology company that develops medical solutions for the early detection and treatment of cancer. The company develops the NeoNavia biopsy system that helps to collect samples from breast lesions or axillary lymph nodes for diagnostic analysis of b …
  • Naval Group:戦略・SWOT・企業財務分析
    Naval Group - Strategy, SWOT and Corporate Finance Report Summary Naval Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • 3D Signatures Inc (DXD):医療機器:M&Aディール及び事業提携情報
    Summary 3D Signatures Inc (3D Signatures) is a developer of diagnostic and prognostic products for cancers and neurological disorders. The company's pipeline products include 3D Telo-PC a tool that is used to treat prostate cancer. It also provides 3D Telo-RS a diagnostic and prognostic tool used fo …
  • Hualan Biological Engineering Inc (002007):企業の財務・戦略的SWOT分析
    Summary Hualan Biological Engineering Inc (Hualan Biological) is a biopharmaceutical company that develops vaccines. The company conducts research, develops and produces plasma, vaccines and gene products. Its plasma products include surgical lyophilized fibrin sealant, human coagulation factor VIII …
  • Ramaco Resources Inc. (METC):企業の財務・戦略的SWOT分析
    Ramaco Resources Inc. (METC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • NetApp Inc:企業の戦略・SWOT・財務情報
    NetApp Inc - Strategy, SWOT and Corporate Finance Report Summary NetApp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Randstad Holding nv:企業の戦略・SWOT・財務情報
    Randstad Holding nv - Strategy, SWOT and Corporate Finance Report Summary Randstad Holding nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Elasmogen Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Elasmogen Ltd (Elasmogen), formerly Pacific Shelf 1760 Ltd, is a biopharmaceutical company which focuses on the development of soloMER products for the treatment of auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical can …
  • Avis Budget Group, Inc.:戦略・SWOT・企業財務分析
    Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Laboratorios SALVAT SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorios SALVAT SA (SALVAT) is a manufacturer of pharmaceutical products for healthcare industries. The company offers prescription and over-the- counter drugs in various segments such as personal healthcare, metabolism, urology, ophtholmology, dermatology and malaria. Its personal healt …
  • Moss Bros Group Plc (MOSB):企業の財務・戦略的SWOT分析
    Moss Bros Group Plc (MOSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Prism Medical Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Prism Medical Ltd (Prism Medical), a subsidiary of Handicare AB is a medical device company that manufacturer and provides durable medical equipment. The company offers products such as fixed ceiling lifts, portable ceiling lifts, portable track systems, mobile floor lifts, sling systems, ho …
  • Becton, Dickinson:企業のM&A・事業提携・投資動向
    Becton, Dickinson - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Becton, Dickinson Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • City Holding Co (CHCO):企業の財務・戦略的SWOT分析
    City Holding Co (CHCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆